Sign In
Buy ALLO
$2.00
-0.0500 (-2.44%)
At Close: Jun 03, 2026
All You Need to Know About Allogene Therapeutics (ALLO) Rating Upgrade to Buy
01:01pm, Wednesday, 04'th Jun 2025
Allogene Therapeutics (ALLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
SOUTH SAN FRANCISCO, Calif., June 01, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment
03:37pm, Thursday, 29'th May 2025
Allogene's off-the-shelf CAR-T therapies offer scalable, rapid solutions with a diversified pipeline targeting hematologic malignancies, solid tumors, and autoimmune diseases. Upcoming ASCO data, espe
Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade)
09:43am, Wednesday, 28'th May 2025
Allogene Therapeutics continues to advance its pipeline, with notable progress in key clinical trials and upcoming data readouts. The company's financial position remains stable, supported by a strong
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
08:30am, Friday, 23'rd May 2025
SOUTH SAN FRANCISCO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR
SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR
Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:36am, Thursday, 15'th May 2025
Allogene Therapeutics (ALLO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts
Allogene's Q1 Earnings In Line With Estimates, Sales Nil
07:30am, Wednesday, 14'th May 2025
ALLO's first-quarter earnings match estimates. Devoid of marketed products, the company records nil sales in the quarter.
Allogene Therapeutics, Inc. (ALLO) Q1 2025 Earnings Call Transcript
10:47pm, Tuesday, 13'th May 2025
Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q1 2025 Earnings Conference Call May 13, 2025 5:00 PM ET Company Participants Christine Cassiano - EVP, Chief Corporate Affairs & Brand Strategy Officer Davi
Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update
04:05pm, Tuesday, 13'th May 2025
Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Nearly 50 Sites Activated Across U.S. with Strong Enthusiasm f
Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update
08:30am, Tuesday, 06'th May 2025
Conference Call and Webcast Scheduled for May 13, 2025 at 2:00 p.m. PT/5:00 p.m.
SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC
FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug
07:50am, Tuesday, 08'th Apr 2025
The FDA's fast track designations will facilitate rapid development and expedited review of ALLO's autoimmune disease candidate.
SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC
Allogene's Q4 Loss Narrower Than Expected, Revenues Nil
08:56am, Friday, 14'th Mar 2025
ALLO's fourth-quarter earnings beat estimates. Devoid of marketed products, the company records no sales in the quarter.
